A modified model of graft‐versus‐host–induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease
Open Access
- 5 April 2004
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 50 (4) , 1319-1331
- https://doi.org/10.1002/art.20160
Abstract
Objective Diffuse systemic sclerosis (SSc; scleroderma) is a debilitating disease characterized by excessive dermal fibrosis with later progression to internal organs. In addition to the fibrotic component, major aspects of the disease include vascular or circulatory involvement and immune dysregulation evidenced by inflammatory cells in affected tissues and production of autoantibodies. Many animal models resembling this disease have been studied, including genetic models in mice and chickens, challenge with chemicals such as bleomycin or vinyl chloride to induce fibrosis, and models of graft-versus-host (GVH)–induced disease using certain strains of mice with differences in minor histocompatibility loci. The present studies were undertaken to determine if alteration of the induction of GVH-induced scleroderma could result in a model that more fully represented the human condition. Methods Disease was induced by injection of spleen cells from B10.D2 mice into BALB/c mice deficient in mature T and B cells (recombination-activating gene 2 targeted). Dermal thickening, collagen deposition, vasoconstriction, and parameters of immunity were analyzed. Results Similar to the human disease, this modified GVH model of SSc demonstrated evidence of dermal thickening, particularly in the extremities, progressive fibrosis of internal organs, vasoconstriction and altered expression of vascularity markers in skin and internal organs, early immune activation, inflammation in skin and internal organs, and autoantibody generation. Conclusion This modified model of GVH-induced SSc exhibits all major components of human disease and is likely to contribute to better understanding of the disease mechanisms and, ultimately, improved treatments for patients.Keywords
This publication has 45 references indexed in Scilit:
- Animal Model of Sclerotic Skin Induced by Bleomycin: A Clue to the Pathogenesis of and Therapy for Scleroderma?Clinical Immunology, 2002
- Susceptibility to Cyclosporin A-induced Autoimmunity: Strain Differences in Relation to Autoregulatory T CellsJournal of Autoimmunity, 2002
- Novel therapy in the treatment of sclerodermaExpert Opinion on Investigational Drugs, 2001
- Systemic Sclerosis: New Insights in AutoimmunityProceedings of the Society for Experimental Biology and Medicine, 1999
- Systemic Sclerosis: New Insights in AutoimmunityProceedings of the Society for Experimental Biology and Medicine, 1999
- Increased levels of type I and III collagen and hyaluronan in scleroderma skinBritish Journal of Dermatology, 1997
- FAMILIAL SCLERODERMA—EVIDENCE FOR ENVIRONMENTAL VERSUS GENETIC TRIGGERRheumatology, 1994
- Suppressor function of hepatic mononuclear inflammatory cells during murine chronic graft-vs-host disease: I. Macrophage-enriched cells mediate suppression in the liverCellular Immunology, 1991
- Immunoglobulin dysregulation in murine graft-vs-host disease: A hyper-IgE syndromeClinical Immunology and Immunopathology, 1990
- Chronic graft-versus-host disease (GVHD) as a model for sclerodermaCellular Immunology, 1983